Excited to share a newly published review in the prestigious Cardiovascular Research journal, highlighting the pathogenic role of CD8+ T lymphocytes in cardiovascular diseases — the result of a collaborative effort by leading international experts.​​At POLYGON Therapeutics, we are developing the first-in-class, fully human monoclonal anti-CD8 antibody designed to reduce the cardiovascular burden of atherosclerosis and address severe cardiac conditions with limited treatment options, such as myocarditis.​​Our lead candidate, PLG-101, now approaching clinical development, holds strong multi-indication potential.

Article is available through the following link.